Hoppa till innehållet
OMXsum
← Marknaden
Report invitationNanoform Finland

Nanoform Finland: Invitation to Nanoform’s Q2 2026 Report Presentation

Kursreaktion
−7,1 %
Sedan publicering
Volym / normalt
Saknas
Första 5 min
Volym / före
Saknas
Första 5 min

Aktiekurs

Mätpunkter & underlag

Aktien idag

Senaste kurs
Äldre data

22 sep. 11:34

Föregående stängning
10,62 SEK

2026-09-21

Handlad volym
Saknas

22 sep. 11:34

Jämförelseunderlag
0 handelsdagar · preliminärt

RVOL vid samma tid jämför den kumulativa volymen med samma klockslag tidigare handelsdagar. RVOL mot heldag jämför med snittet för 20 hela handelsdagar. Det är bolagets handel, inte volym orsakad av nyheten.

Handelsdagen ovan är senare än nyhetens första börssession.

Leverantörens stängningskurs; justering för bolagshändelser är inte verifierad.

Läs hela källtexten

Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q2 2026 report August 20th, 2026, at 8.10 a.m. EET / 7.10 a.m. CET.

Nanoform Finland Plc | Press Release | August 06, 2026 at 11:00:00 EEST Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q2 2026 report August 20th, 2026, at 8.10 a.m. EET / 7.10 a.m. CET. The company will hold an online presentation and conference call the same day at 11.00 a.m. EET / 10.00 a.m. CET. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones and CDO & GC Peter Hänninen. The presentation will be delivered in English. The presentation will be broadcasted live and participants may access the event via live audiocast and teleconference through the following link: https://investorcaller.com/events/nanoform/nanoform-q2-report-2026 To participate in the event, attendees are required to register. To join the Q&A session, participants must dial in to the teleconference. After registering, they will receive a dial-in number, a conference ID, and a personal user ID to access the conference. Please note that questions can only be submitted through the teleconference line. For further information, please contact: Henri von Haartman, Director of Investor Relations hvh@nanoform.com +46 7686 650 11 About Nanoform Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se (mailto:certifiedadviser@carnegie.se). For more information, please visit www.nanoform.com (http://www.nanoform.com/). Attachments Invitation to Nanoform’s Q2 2026 Report Presentation (https://storage.mfn.se/c191ab71-641e-43d6-ba36-2998f2ddaf86/invitation-to-nanoforms-q2-2026-report-presentation.pdf)

Källor & underlag

Fortsätt till nyhetsflödet Dina bevakningar